New antibody drug shows promise in early blood cancer trial
NCT ID NCT04540796
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new drug called JNJ-75348780 in 147 people with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia. The drug is a bispecific antibody designed to help the immune system attack cancer cells. The main goals were to check safety and find the right dose for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-75348780 (a bispecific antibody that targets CD3 and CD22 proteins on immune and cancer cells)
What this could lead to
If successful, this could lead to a new treatment option for people with certain blood cancers that have not responded to other therapies.
What could go wrong
This is an early Phase 1 trial focused on safety and dosing, so it is not yet known if the drug works. Side effects, including immune reactions, are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Austin Hospital
Heidelberg, 3084, Australia
-
CHRU de Lille Hopital Claude Huriez
Lille, 59037, France
-
CHU Nantes
Nantes, 44093, France
-
Carmel Medical Center
Haifa, 34362, Israel
-
Centre hospitalier Lyon-Sud
Pierre-Bénite, 69495, France
-
Chang-Gung Memorial Hospital, Kaohsiung
Kaohsiung City, 83301, Taiwan
-
China Medical University Hospital
Taichung, 40402, Taiwan
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Hadassah Medical Center
Jerusalem, 9112001, Israel
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp. Univ. Germans Trias I Pujol
Barcelona, 8916, Spain
-
Hospital de Vall D'Hebron
Barcelona, 08035, Spain
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Kings College Hospital
London, SE5 9RS, United Kingdom
-
Leicester Royal Infirmary
Leicester, LE1 5WW, United Kingdom
-
Linear Clinical Research Ltd
Nedlands, 6009, Australia
-
National Cheng Kung University Hospital
Tainan, 70403, Taiwan
-
National Taiwan University Hospital
Taipei, 10048, Taiwan
-
Plymouth Hospital NHS Trust
Plymouth, PL6 8DH, United Kingdom
-
Rambam Medical Center
Haifa, 31096, Israel
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Severance Hospital Yonsei University Health System
Seoul, 03722, South Korea
-
Sheba Medical Center
Ramat Gan, 74047, Israel
-
Taichung Veterans General Hospital
Taichung, 40705, Taiwan
-
Tel Aviv Sourasky MC
Tel Aviv, 6423906, Israel
-
The Catholic University of Korea Seoul St Marys Hospital
Seoul, 06591, South Korea
-
The Christie Nhs Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35233, United States